Emmaus Life Sciences develops treatments and therapies for rare and orphan diseases, with a commercial focus on Endari (L-glutamine oral powder), its prescription treatment for sickle cell disease approved by the FDA in 2017. The company intended to use new financing to support the commercial launch of Endari by expanding sales/marketing and research and development. Emmaus also conducts tissue‑engineering research aimed at generating healthy cells from a patient’s own cells to eliminate donor waits and reduce rejection risk. The company is led by Chairman and CEO Yutaka Niihara, MD, MPH. To support operations and refinance existing debt, Emmaus received a debt investment in 2018. No operating metrics were disclosed in the article. Emmaus Life Sciences is focused on the discovery, development and commercialization of innovative, cost-effective treatments and therapies for debilitating rare diseases. The company is developing a treatment for sickle cell disease that is in a Phase 3 clinical trial. Emmaus intends to use recently raised funds to complete that Phase 3 trial and to support commercialization activities. Proceeds will also cover working capital and general corporate purposes. The company is led by Yutaka Niihara, MD, MPH, who serves as CEO, President and Director. The report notes the company is based in Torrance, California.

Total raised

$38M

Funding rounds

2

Latest round

Convertible Note

Latest activity

Jan 2018